September 2023 marked a historic moment as MAPS (Multidisciplinary Association for Psychedelic Studies) published satisfactory results for phase 3 FDA trials that are paving the way for FDA approval of MDMA as a treatment for PTSD for the general public. Now we may see MDMA as an approved treatment as early as next year.
During this week’s Kentucky Opiate Abatement Commission hearing, Rick Doblin, President and Founder of MAPS, shared that it was a very long journey behind this achievement.
Nevertheless, MAPS may now be setting its sights on ibogaine, an extraordinary plant from Africa that has shown to heal those struggling with opioid use disorder (OUD), depression and PTSD.
Watch the last and final KY Opiate Abatement Commission hearing:
